





The world's population is getting larger, older and sicker



Population will increase by



Additional 50+ year olds



Chronic diseases

billion

>500 million


70% of all illness

 $2015 - 2025^{1}$






Healthcare systems face significant challenges in expanding access to healthcare, while managing finite resources



Despite the challenges, with over 7,000 medicines in development, new diagnostic techniques, genomic research and advances in data analytics there are many reasons to be optimistic about a

Healthier future for Europe





Key questions to address.....

How do you introduce high impact – high value, transformative technologies in to healthcare systems?

How do you make systems more sustainable in the future?






Healthcare expenditure has been growing since the 1990s while pharmaceutical spending declined from 2010 to 2013

Across Europe, expenditure on total healthcare are growing faster than growth in pharmaceutical expenditure

Expenditure per capita (2004-2012, 25 European OECD Countries, population-weighted, current prices, PPP, \$)





⁻ Pharmaceutical Expenditure per Capita (2004 = Index 100)






Medication costs represent a small percentage of total disease spending



In Germany, medication spending is a small share of the total cost of many chronic diseases







Recommendations for introducing new technologies

Updating regulatory guidance & procedures

Regulatory guidance is needed to ensure that manufacturers are able to generate the necessary information for HTA / EMA stakeholders to make informed decisions minimising access delays

Providing temporary access with clinical uncertainty

RWE generation through temporary access schemes should continue to be utilised to mitigate the benefit uncertainty at launch given limited data

Valuing and rewarding innovation

Continual adaptation of HTA / value assessment processes in order to fairly assess and reward the long term clinical, economic and societal value of innovation; given possibility of limited evidence at launch or large patient populations

Adapting financing models for upfront investment

Innovative finance models such as annuities should be considered given the long-term, system-wide benefits; these will help overcome limits posed by annual as well as siloed budgets

Incentivising treatments to address societal need e.g.

Stimulating innovation in an area where there has been little activity and failure to do so could have huge repercussions for society in the future requires funding solutions to numerous scientific, regulatory and business barriers



Recommendations for introducing new technologies

Developing novel, integrated care delivery pathways

Health systems and industry should collaborate in order to develop the necessary infrastructure to successfully deliver treatments, as some may not fit traditional pharmaceutical delivery pathways

Optimising patient/ treatment strategies

HCSs and manufacturers need to work together to optimise approaches to managing patients; collaboration is key to optimise patient outcomes and reduce the risk of adverse events

Improving data collection infrastructure

Infrastructure able to deliver reliable real world data in a timely manner is key to ensure that stakeholders can quickly make informed decisions regarding access and delivery of innovations



Why the focus on outcomes?

EFPIA believes an outcomes-based system will do a better job of stimulating and rewarding real innovation – the innovation that benefits patients most, and supports health system sustainability







Delivering better outcomes for patients

The objective of outcomes-focused healthcare systems are to deliver better patient outcomes at the same or lower cost...

...relying on quality outcomes data as the starting point for improving the care cycle










There is an estimated 20-40% waste in health systems, with practice variation accounting for half

There is a ~30% of waste estimated, with practice variation representing half of it

Mean estimate of HC inefficiencies for the 3 country-types combined (%)^a



20-40% of waste for the 3 country-types

Top-down estimate of inefficiencies on low, mid and high-income countries at 20-40% of HC costs

- Mean: 27% of HC costs
- ~50% of inefficiencies in all country types are associated with intervention mix

Differences in inefficiencies (%) by category vary across country types, but are mainly driven by differences in the category's share of total HC costs

 e.g. 10-15% of medicine costs result in 2-5% of total HC costs






b. For example, the use of non cost-effective interventions



c. Overlap has been subtracted proportionally from these categories

Outcomes vary widely among OECD countries

2010-2012 OECD Health outcomes indicators







Barriers to an outcomes-based healthcare system



Technical barriers

Outcomes-based healthcare relies on delivering value, measured as health outcomes divided by cost. It is based on the ability to capture, analyse and utilise outcomes (and financial) data, with standardised definitions of outcomes at the core. Today, the measurement of outcomes is not common practice. Many providers and healthcare systems do not know which outcomes they achieve in which disease area.



Structural barriers

The most significant structural barrier is the fragmentation of healthcare systems. Individual organisation within a healthcare system often have different definitions of outcomes, different incentives and targets, and alternative preferred care pathways.



Financial barriers

Instead of rewarding the long-term improvement of a patient's health, fiscal incentives tend to reward process related measures like adherence to clinical guidance, the number of times a doctor talk to his or her patients about prevention and healthy lifestyles, the number of patients of a certain category that are referred to a specialist or prescribed a certain medication.



Political barriers

System-wide, transformational change is challenging, it quires strong political commitment over a number of years to make it happen. Implementing some outcome-based decisions such as closing hospitals or the transferring of care to the community can invoke string reactions from local stakeholders who are attached to particular services. The concept of outcomes-based healthcare is intellectually attractive but its implementation can include some difficult, sometimes politically unpopular decisions.













Analyse variation

Data analytics provides the key to identifying variances in care and their impact on outcomes, to detect sources of waste and inefficiencies in the system.



Identify best practice

Standardised outcomes measures and quality and transparent outcomes data, coupled with the use of data analytics, will facilitate the identification of best practice for replication across health systems.



Promote proof of concepts

Pilots that have successfully improved outcomes in a specific patient population build trust in the merits of an outcomesbased approach and provide important clues about the practicalities of implementing outcomes-based healthcare.



Develop integrated health information systems

Tools such as electronic health records, disease registries and user-friendly data capture systems all contribute to developing an outcomes-based system.



Build a health data eco-system

To spark, develop and deliver change, data needs to be of high quality and shared across the healthcare system, for quality improvement and research.



Feedback and learn

As clinical practice and service delivery changes, real world evidence and data analytics provide a mechanism for real-time learning and continuous development.



Remove budget siloes and reward quality of care

Establishing flexible and holistic finance systems that promote care integration, and payment models that reward good health outcomes for patients can help facilitate change.





